Page 18 - SOGIBA 1 2020

Caso Clínico

of adverse events in the treatment of patients with anti-beta2 glycoprotein I antibodies measurement
immunoglobulin ther- apy: a review of evidence. by commercial assays. Thromb Haemost 2005;94
Autoimmun Rev 2016;15(01):71–81 (03):665–672

• El-Haieg DO, Zanati MF, El-Foual FM. Plasma- • Pengo V, Biasiolo A, Bison E, Chantarangkul V,
pheresis and preg- nancy outcome in patients Tripodi A; Italian Federation of Anticoagula-
with antiphospholipid syndrome. Int J Gynaecol tion Clinics (FCSA). Antiphospholipid antibody
Obstet 2007;99(03):236–241 ELISAs: survey on the performance of clinical
labora- tories assessed by using lyophilized
• Ruffatti A, Favaro M, Hoxha A, et al. Apheresis
and intravenous immunoglobulins used in addi- affinity-purified IgG with anticardiolipin and
tion to conventional therapy to treat high-risk anti-beta2-Glycoprotein I activity. Thromb Res
pregnant antiphospholipid antibody syndrome 2007;120(01):127–133
patients. A prospective study. J Reprod Immunol • Favaloro EJ, Wheatland L, Jovanovich S, Roberts-
2016;115:14–19 Thomson P, Wong RC. Internal quality control and
• Reber G, Tincani A, Sanmarco M, de Moerloose P, external quality assurance in testing for antiphos-
Boffa MC; European Forum on Antiphospholipid pholipid antibodies: Part I–Anticardiolipin and
Antibodies Standardiza- tion Group. Variability of anti-β2-glycoprotein I antibodies. Semin Thromb
Hemost 2012;38(04):390–403

16 Revista de Obstetricia y Ginecología de Buenos Aires